Neurology Search
Neurology Neurology
migraine%20headache
MIGRAINE HEADACHE
Migraine headache without aura has at least 5 attacks of any 2 symptoms of unilateral headache that is throbbing or pulsating in nature, moderate to severe in pain and activity aggravates pain. It is accompanied with either nausea and vomiting or photophobia and/or phonophobia. The symptoms last for 4-72 hours without signs of secondary headache.
Migraine headache with aura has at least 2 attacks with any of the fully reversible symptoms of flickering lights, spots or lines and/or vision loss, sensory symptoms of pins and needles and/or numbness and dysphasic speech disturbance but without motor weakness. Accompanied by at least 2 of the following symptoms of homonymous visual symptoms and/or unilateral sensory symptoms or at least 1 aura symptom develops gradually over ≥5 minutes and/or different aura symptoms that occur in succession over ≥5 minutes.

Migraine%20headache Signs and Symptoms

Definition

 Migraine Headache

  • A common episodic primary headache that is disabling with associated nausea and/or light and sound sensitivity

 Phases of migraine attack

  • Prodrome - appears 24-48 hours before headache occurs
  • Aura - occurs in 25% of individuals with migraine which is often visual but can be sensory, verbal or motor disturbances
  • Headache - usually unilateral with throbbing or pulsatile quality and accompanying nausea, vomiting, photophobia or phonophobia
  • Postdrome

Epidemiology

  • Based on World Health Organization (WHO), 0.5-0.75 of adults aged 18-65 years old in the world have had headache in 2015 and ≥30% of them have reported having migraine headache
  • Ranked as the 3rd most prevalent disorder in the world based on the Global Burden of Disease Survey 2010 (GBD 2010) and ranked as the 3rd-highest cause of disability in the world among males and females <50 years old based on GBD 2015
  • According to the United Nations, there are 350 million individuals that have migraine headache in the Asia-Pacific region

Pathophysiology

  • It is hypothesized that cortical spreading depression causes the aura of migraine, activates trigeminal nerve afferents and alter blood-brain barrier permeability by matrix metalloproteinase activation and upregulation
    • Activation of trigeminal nerve afferents causes inflammatory changes in the pain-sensitive meninges that generates the headache that occur in migraine through central and peripheral reflex mechanisms
  • Pathophysiology of migraine includes activation of the trigeminovascular system and the pain of migraine is linked to the onset of neurogenic inflammation
  • Clinical symptoms of migraine is due to the process called sensitization in which neurons become increasingly responsive to nociceptive and non-nociceptive stimulation

Signs and Symptoms

Premonitory and resolution symptoms include

  • Hyperactivity
  • Hypoactivity
  • Depression
  • Cravings for particular foods
  • Repetitive yawning
  • Fatigue
  • Neck stiffness and/or pain
Editor's Recommendations
Most Read Articles
Denosumab, alendronic acid show null effect on aortic valve calcification
07 May 2021
Both denosumab and alendronic acid fall short of reducing disease progression in patients with calcific aortic stenosis, a study has shown.
A non-pharmaceutical approach to managing migraine and headache
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
Amphetamine patch for paediatric ADHD: Does evidence support its use?
Elvira Manzano, 06 May 2021
An investigational transdermal amphetamine patch worn for 9 hours on the hip appeared effective in paediatric patients with attention deficit-hyperactivity disorder (ADHD) in a phase II, two-part trial.
Cannabidiol for Lennox–Gastaut syndrome takes effect within a week
6 days ago
The effect of cannabidiol (CBD) in the treatment of patients with Lennox–Gastaut syndrome may occur within 7 days of initiation, and most adverse events resolve within a 14-week period, a study reports.